Osteal Therapeutics
 United States
                                                 -                                                 Dallas, TX
                                                                                                                                    
                                                                                                United States
                                                 -                                                 Dallas, TX
                                                                                            
                                                                                    - 26/09/2023
- Series C
- $23,000,000
Osteal Therapeutics is a privately-held, clinical-stage pharmaceutical company developing novel musculoskeletal therapeutics to treat orthopedic infections and their consequences.
- Industry Pharmaceutical Manufacturing
- Website https://www.linkedin.com/company/osteal/about/
- LinkedIn https://www.linkedin.com/company/osteal/people/
Related People
David ThompsonFounder
 United States -
                                                         Dallas, Texas
                                                    
                                                                                                                United States -
                                                         Dallas, Texas
                                                    
                                                Business leader and healthcare entrepreneur with over 25 years of experience in organizations of all sizes developing new technology and new markets in the U.S. and internationally with a particular focus on medical devices, digital health and diagnostics.
Particularly passionate about early stage ventures and intrapreneurial opportunities that require market analysis, needs assessment, product and business model discovery and definition, corporate strategic planning, and go-to-market execution. 
PROFICIENCIES:
Leadership • General Management • Global Strategic Planning • Organization Building • Innovation • Sales • Marketing • Commercial Execution • P&L Management • Business Development • Alliance Management • Fundraising • New Product Launch • Product Development • Cross-Functional / Matrix Leadership • Pipeline Management
MEDICAL SPECIALTIES: 
Rare Disease Therapeutics • Spine Orthopedics Gastroenterology • Diabetes • Orthopedic Reconstruction • Sports Medicine • Orthotics and Prosthetics • Wound Care • Critical Care
TECHNOLOGIES:
Combination Products • Implants • Disposables • Surgical Instrumentation • Point-of-Care Diagnostics • Capital Equipment 
 Vesence |  $9,000,000  | (Oct 30, 2025)
                                Vesence |  $9,000,000  | (Oct 30, 2025) Sparrow BioAcoustics |  $10,000,000  | (Oct 30, 2025)
                                Sparrow BioAcoustics |  $10,000,000  | (Oct 30, 2025) 
                             Reflectiz |  $22,000,000  | (Oct 30, 2025)
                                Reflectiz |  $22,000,000  | (Oct 30, 2025) 
                             
                                     
                                     
                                     
                                     
                                     
                                             
                                                 
                                                     
                                                     
                                                     
                                                     
                                                     
                                                     
                                                 
                                                 
                                                 
                                                 
                                                 
                                                     
                                                 
                                                 
                                                 
                                                     
                                                 Mem0 |  $24,000,000  | (Oct 30, 2025)
                                                                        
                                Mem0 |  $24,000,000  | (Oct 30, 2025) Valthos |  $30,000,000  | (Oct 30, 2025)
                                                                        
                                Valthos |  $30,000,000  | (Oct 30, 2025) Mondra |  $13,206,500  | (Oct 30, 2025)
                                                                        
                                Mondra |  $13,206,500  | (Oct 30, 2025) hoop.dev |  Undisclosed Amount  | (Oct 30, 2025)
                                                                        
                                hoop.dev |  Undisclosed Amount  | (Oct 30, 2025) IORGANBIO |  $2,000,000  | (Oct 30, 2025)
                                                                        
                                IORGANBIO |  $2,000,000  | (Oct 30, 2025) FrontlineIQ |  $3,300,000  | (Oct 30, 2025)
                                                                        
                                FrontlineIQ |  $3,300,000  | (Oct 30, 2025) Homecourt |  $8,000,000  | (Oct 30, 2025)
                                                                        
                                Homecourt |  $8,000,000  | (Oct 30, 2025) VentureMed Inc. |  $28,000,000  | (Oct 30, 2025)
                                                                        
                                VentureMed Inc. |  $28,000,000  | (Oct 30, 2025) Recess |  $30,000,000  | (Oct 30, 2025)
                                                                        
                                Recess |  $30,000,000  | (Oct 30, 2025)